Centiva Capital’s United Therapeutics UTHR Stock Holding History

Centiva Capital’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-31,500	Closed	-$18.7M	–	2227
2026 Q1	$18.7M	Buy	+31,500	New	+$15.7M	0.14%	112

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Norges Bank Oslo, Norway $1T AUM

Centiva Capital's UTHR Position: Q3 2024 in Review

Centiva Capital sold out of United Therapeutics (UTHR) in Q3 2024, closing a stake of 2,656 shares — an estimated $846K sold.

Centiva Capital first reported a position in UTHR in Q4 2019 and held it in 7 quarters. The position peaked at $846K in Q2 2024. 625 funds tracked by Wall St. Rank hold UTHR as of Q3 2024.

Centiva Capital reported no remaining United Therapeutics position as of Q3 2024 after selling out during the quarter.
Centiva Capital sold 2,656 United Therapeutics shares in Q3 2024, an estimated $846K.
Centiva Capital first reported a position in United Therapeutics in Q4 2019 and held it in 7 quarters.
Centiva Capital's United Therapeutics position peaked at $846K in Q2 2024.
625 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2024.

Based on Centiva Capital's 13F filing for Q3 2024, filed 14 Nov 2024.